Resveratrol is probably the single most famous “longevity compound” in supplement history — a polyphenol found in red grape skins that became attached to the sirtuin/SIRT1 story, calorie-restriction mimicry, and the “French paradox.” It's also a useful case study in what happens when a compelling mechanistic story runs ahead of the human clinical evidence for two decades. The honest picture in 2026 is more complicated than most marketing suggests, and it deserves to be reported straight.
Where the story started
The modern resveratrol narrative traces to a 2006 paper by Baur, Sinclair, and colleagues showing resveratrol improved health and survival in mice on a high-calorie diet, building on earlier biochemical work suggesting resveratrol could directly activate SIRT1, an NAD+-dependent deacetylase enzyme linked to longevity pathways in lower organisms.1 The commercial stakes were significant from early on: David Sinclair co-founded Sirtris Pharmaceuticals on the resveratrol/SIRT1 thesis, and GlaxoSmithKline acquired the company for approximately $720 million in 2008 to develop sirtuin activators.2
What happened to the mechanism
Two things are important to separate here: whether resveratrol directly activates SIRT1 the way originally proposed, and whether resveratrol supplementation raises SIRT1 activity in actual human trials.
On the first question, subsequent biochemical work found that resveratrol's apparent direct SIRT1 activation in the original in vitro assays was substantially an artifact of the fluorescent-tag-based assay methodology used — the effect was much weaker or absent when tested with the enzyme's native, untagged substrates.2 GSK closed the Sirtris labs in 2013 after failing to validate the mechanism through clinical development.2
On the second, more directly relevant question — does resveratrol supplementation raise SIRT1 in humans — a 2025 GRADE-assessed systematic review and dose-response meta-analysis pooled 11 randomized controlled trials examining resveratrol's effect on SIRT1 gene expression (4 RCTs), protein expression (5 RCTs), and serum levels (3 RCTs).3 The results were uniformly null: no significant effect on SIRT1 gene expression (SMD 0.05, 95% CI −0.24 to 0.34, P=.73), protein expression (SMD 0.3, 95% CI −0.15 to 0.77, P=.18), or serum levels (MD −0.04, 95% CI −0.235 to 0.16, P=.7).3
A complicating data point
Not every trial fits this null pattern cleanly. A 2023 randomized trial comparing resveratrol supplementation to energy restriction in 48 healthy adults aged 55–65 found both interventions increased circulating SIRT1significantly (p<0.001), alongside effects on vascular reactivity measures.4 This is a genuine point of tension in the literature rather than a settled contradiction — it's one trial against a meta-analysis of eleven, and trial-to-trial differences in resveratrol formulation, dose, and the specific SIRT1 measurement method likely explain at least some of the disagreement. The honest summary is that the balance of evidence, weighted toward the larger meta-analytic pool, does not support a reliable SIRT1-elevating effect — but the picture isn't unanimous.
What the animal lifespan data actually showed
The original mouse survival benefit from the 2006 Baur study is also more specific than it's often represented: the lifespan extension was observed in mice on a high-calorie diet — resveratrol offset some of the harm of overfeeding — rather than extending healthy lifespan in animals on a normal diet.2 That's a meaningfully narrower finding than “resveratrol extends lifespan” as it's often summarized.
Where this leaves resveratrol as an ingredient
None of this means resveratrol is without any biological activity — it has documented antioxidant and anti-inflammatory effects studied independently of the SIRT1 mechanism, and human research in this area continues. But the specific “activates SIRT1 to mimic caloric restriction and extend life” narrative that made resveratrol famous rests on a mechanism that hasn't held up well under closer investigation, and the largest human meta-analysis to date found no significant SIRT1 effect at all. Bioavailability remains a separate, genuine challenge on top of this — resveratrol is poorly absorbed and rapidly metabolized, which is part of why trial results have been inconsistent regardless of the underlying mechanism question.5
The practical takeaway
Resveratrol's honest claim territory right now is narrower than its reputation: real antioxidant chemistry, a genuinely contested SIRT1 effect in humans (leaning toward “not established” per the strongest available evidence), and an animal lifespan finding specific to overfed mice rather than general life extension. Marketing copy built on “activates SIRT1 for longevity” as settled fact is stating something the 2025 meta-analysis specifically did not find.